The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked sufficient evidence to support claims of safety, efficacy, and personalized formulation, as the evidence mainly related to FDA-approved tirzepatide drugs by Lilly, not compounded versions. Good Life has agreed to comply despite disagreeing with the decision. This ruling affects advertising practices for compounded weight loss medications and highlights the need for substantiated claims in health product marketing.
Eli Lilly And Co (LLY) shares are up 0.84% at USD 1,421.27 as of Nov 04, 2026 23:12 WIB on Pluang. The stock sees a typical hold time of 94 days and a dividend yield of 0.49%, with 59% of Pluang orders to buy. This trading activity occurs alongside the NAD's recommendation affecting compounded tirzepatide products.
Eli Lilly is positioned as a key beneficiary of AI in drug discovery, using its scale and research capabilities to speed up new molecule development and expand its product portfolio. Despite a high forward price-to-earnings ratio of 40, the company i...
Eli Lilly reported a 39% increase in revenue driven by a 53% rise in volume, despite a 15% decline in realized prices. The company's gross margin improved to 83.9%, reflecting strong operational efficiency. Most revenue comes from the obesity drug ti...
Eli Lilly reported a robust third quarter with revenue up 38.6% to $24.4 billion, driven by a 53% increase in tirzepatide volume. CEO David Ricks emphasized growth beyond weight-loss drugs, highlighting advances in immunology, oncology, and neuroscie...
The AI-driven bull market faces challenges as investors rotate from high-spending tech stocks like Nvidia to traditionally defensive stocks such as Walmart and Eli Lilly. Despite strong earnings in some tech sectors, the Nasdaq-100 and semiconductor ...
Eli Lilly reported strong recent financial results with solid revenue growth and robust margins, even raising its guidance. However, signs of slowing revenue growth in the near future could impact margins and temper enthusiasm. Despite this, Eli Lill...
